Showing Results for
- Academic Journals (141)
Search Results
- 141
Academic Journals
- 141
-
From:eLife (Vol. 7) Peer-ReviewedIn 2016, as part of the Reproducibility Project: Cancer Biology (https://osf.io/e81xl/wiki/home/), we published a Registered Report (Vanden Heuvel et al., 2016), that described how we intended to replicate selected...
-
From:Oncology (Vol. 35, Issue 4) Peer-ReviewedOvarian cancer is the fifth most common cause of cancer deaths in women and the leading cause of death among cancers of the female reproductive system in the United States. More than 21,400 women in the United States are...
-
From:Indian Journal of Cancer (Vol. 59, Issue 5) Peer-ReviewedByline: Chirag. Desai, Anand. Pathak, Sewanti. Limaye, Vashishth. Maniar, Archita. Joshi Standard therapy for advanced ovarian cancer (OC) consists of radical debulking cytoreductive surgery followed by adjuvant...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-ReviewedBackground Novel therapeutic strategies are urgently needed for the treatment of metastatic Urothelial Bladder Cancer. DNA damaging repair (DDR) targeting has been introduced in cinical trials for bladder cancer...
-
From:eLife (Vol. 10) Peer-ReviewedPoly(ADP-ribose) polymerase 1 (PARP1) is an important player in the response to DNA damage. Recently, Histone PARylation Factor (HPF1) was shown to be a critical modulator of the activity of PARP1 by facilitating...
-
From:Urology Annals (Vol. 14, Issue 4) Peer-ReviewedByline: Shouki. Bazarbashi, Abdullah. Alsharm, Alaa. Meshref, Hind. Mrabti, Jawaher. Ansari, Marwan. Ghosn, Mohamed. Abdulla, Yuksel. Urun Despite the reliance on Western guidelines for managing prostate cancer (PC),...
-
From:Journal of Toxicology (Vol. 2022) Peer-ReviewedMomordica cochinchinensis or gac fruit has been reported to have several biological activities, including antioxidation, anti-inflammatory, and anticancer activities. However, the effect on cancer cell metastasis has not...
-
From:Nature Medicine (Vol. 22, Issue 2) Peer-ReviewedPoly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer, in clinical trials (1). One PARP inhibitor, olaparib (Lynparza, AstraZeneca), was recently...
-
From:Oncology (Vol. 34, Issue 10) Peer-ReviewedBACKGROUND: Early-phase clinical trials are critical to the advancement of cancer care, especially in patients with pancreatic ductal adenocarcinoma, given its aggressive nature and limited available therapeutic options....
-
From:Breast Cancer (Vol. 28, Issue 3) Peer-ReviewedBackground BRCA1/2 gene mutation testing, based on next-generation sequencing (NGS), has been gradually applied in the clinic to serve as preventive early screening for predisposed individuals or to provide treatment...
-
From:Journal of Hematology & Oncology (Vol. 14, Issue 1) Peer-ReviewedDespite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed. Germinal and/or somatic...
-
From:Journal of Hematology & Oncology (Vol. 13, Issue 1) Peer-ReviewedMetastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 41, Issue 1) Peer-ReviewedBackground Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian cancers (HGSOC) with BRCA1/2 mutations or other deficiencies in homologous recombination (HR) repair...
-
From:Indian Journal of Urology (Vol. 38, Issue 4) Peer-ReviewedByline: Abhay. Gaur Summary The knowledge of homologous recombination repair (HRR) deficiency in certain cancer cells and the advent of poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors has led to a...
-
From:Nature (Vol. 510, Issue 7506) Peer-ReviewedAuthor(s): Heidi Ledford A cancer drug once lauded as a shining example of translational research but cast aside after a disappointing clinical trial may be rising from the ashes. Olaparib was one of the first...
-
From:PLoS ONE (Vol. 14, Issue 12) Peer-ReviewedAlterations of the PALB2 tumor suppressor gene have been identified in familial breast, ovarian and pancreatic cancer cases. PALB2 cooperates with BRCA1/2 proteins through physical interaction in initiation of homologous...
-
From:Indian Journal of Cancer (Vol. 57, Issue 3) Peer-ReviewedByline: Zarka. Samoon, Adnan. Jabbar Ovarian cancer is the most common cause of death among gynecologic cancers and has a cure rate of less than 40% in women.[1] Around 70% of women present with advanced disease, with...
-
From:Oncology (Vol. 34, Issue 10) Peer-ReviewedOvarian cancer is the leading cause of mortality among gynecologic cancers in the United States, (1) expected to result in roughly 13,940 deaths in 2020. (2) Between 2008 and 2017, mortality decreased by 2.3% per year....
-
From:Indian Journal of Cancer (Vol. 57, Issue 4) Peer-ReviewedByline: Peter. Dottino, Matthew. Dashkoff, Ann. Beddoe Over the past three decades, survival among all patients with ovarian cancer has improved. Characteristically, however, 5-year survival from advanced epithelial...
-
From:Hereditary Cancer in Clinical Practice (Vol. 20, Issue 1) Peer-ReviewedBackground Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of...